Osimertinib - a new word in the treatment of lung cancer
Treatment of cancer of all types and types is one of the main tasks of physicians around the world. Oncological diseases of the lungs and the respiratory system are quite common among the most diverse groups of the world's population. Regardless of the lifestyle, external factors and habitat, this ailment can affect anyone. However, scientists create new drugs and procedures every year so that lung cancer patients can fight the disease with the hope of full recovery or long-term remission.
How osimertinib was created
The osimertinib formula began to be developed in 2009. Scientists from the USA were engaged in the synthesis of the substance. Having achieved positive results in the development of a stable form of the substance, they began to research it, using it to treat non-small cell lung cancer. By 2012, the first results were obtained, after which osimertinib was patented and began to be used in the creation of individual drugs. The first osimertinib-based product was Tagrisso, which appeared in 2014. The drug has passed the stage of clinical trials and studies and was approved for widespread use in 2015. Today, drugs containing osimertinib are successfully used by oncologists around the world.
The effect of using osimertinib
Osimertinib is a substance for the treatment of metastatic and advanced non-small cell lung cancer with specific mutations. The substance is an inhibitor of epidermal growth factor receptor kinase, which binds irreversibly to some mutant forms of EGFR. Studies have shown that osimertinib is highly effective against lung cancer. Among other things, oncologists and patients who used drugs with osimertinib note the absence of contraindications and a small number of unpleasant side effects.
Where to buy osimertinib medications?
Modern pharmaceutical companies offer drugs containing osimertinib to fight blood cancer.
In the European part of the world, patients are most often prescribed Tagrisso tablets, which were the first to be launched on the market. However, the cost of the original medicine, which fluctuates around 200 thousand rubles per package, does not allow the majority of patients to use the medicine. An expensive drug, which is enough for one month of admission, while the course assumes a treatment period of up to 24 weeks, not everyone can afford. Due to the high cost of the drug, WHO transferred the license for the production of osimertinib to pharmaceutical companies in India, Egypt and Bangladesh. Thanks to this, drugs with osimertinib appeared on the market, which are significantly cheaper, and are not inferior in quality to the original. You can buy osimertinib tablets in our pharmacy, we offer: • Osicent 80 (Incepta, India) ;
• Osimert 80 (Everest Pharmaceuticals Ltd. Bangladesh) ;
• Tagrix (Beacon Pharmaceuticals. Bangladesh) .
The offered drugs are certified and licensed, which guarantees proper quality. To order drugs containing osimertinib, contact the consultant on our website.